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Nonalcoholic Fatty Liver Disease (NAFLD) is increasing in older adults, but no evidence exists 
on the longitudinal association between NAFLD and cognitive decline at old ages. The aim of 
this 7-year longitudinal study was to examine whether presence of NAFLD at baseline and/or 
its change (i.e. progression or regression) over the follow up predict the rate of cognitive decline 
over the same timeframe in older adults, independent of potential confounders. Participants 
included 457 community dwelling men and women aged 65 to 87 (mean ±SD: 70.9±4.1) years 
old, living near Bologna (Northern Italy). Global cognitive status was evaluated using Mini-
mental State Examination (MMSE). Hepatic steatosis was assessed by abdominal ultrasound 
and categorized as absent, mild, moderate or severe. Participants were also classified into three 
subgroups according to their progression, stability or regression in hepatic steatosis over the 
follow up. Generalized estimating equation (GEE) models with 30 minus MMSE total score as 
the dependent variable with a Poisson distribution were used to test the longitudinal 
associations. Covariates included demographics, education, activities of daily living, alcohol, 
smoke, body mass index (BMI), waist circumference, hypertension, dyslipidemia, diabetes, 
insulin resistance and inflammation. As results, I found no significant association between 
baseline presence/severity of hepatic steatosis and either cross-sectional cognitive status or 
longitudinal rate of cognitive decline (P> .05). In addition, participants who underwent 
regression in the degree of hepatic steatosis over the follow-up presented accelerate cognitive 
decline over the same timeframe compared to the rest of the population, independent of 
covariates and even after adjusting for longitudinal change in BMI and waist circumference (P= 
.03). A nested sensitivity analysis confirmed this trend even when including only participants 
starting from moderate-severe hepatic steatosis at baseline. In conclusion, the present study 
suggests that in older adults NAFLD regression rather than progression is associated with 








NALFD definition, pathogenesis and epidemiology  
Nonalcoholic Fatty Liver Disease (NAFLD) is a pathological condition characterized by 
excessive hepatic fat accumulation associated with insulin resistance and defined by the 
presence of hepatic steatosis on either imaging or histology in individuals without excessive 
alcohol consumption (<20 g/day for women and <30 g/day for men) or other competing causes 
of liver disease1,2.  It is a multifactorial and multisystem disease resulting from complex 
genetics, environmental and metabolic interactions2-4. It currently affects about 25% of the 
world population and it is one of the most common cause of chronic liver disease5, 6. It has been 
estimated that the burden of NAFLD will even increase worldwide in the next decades with a 
tremendous clinical and economic impact7.  
NAFLD and aging  
Aging is characterized by major changes in body composition that negatively affect functional 
status and outcomes in older adults. Particularly, at old ages (≥ 70 years), both fat-free mass 
and fat mass tend to decrease, with consequent decreasing body weight. Moreover, visceral fat 
tends to increase with aging, while subcutaneous fat declines, resulting in increased insulin 
resistance8. Therefore, aging is considered a risk factor for NAFLD. Consistently, data from a 
recent meta-analysis showed that the NAFLD prevalence increases with aging, although studies 
about NAFLD in individuals aged 70 years or older are very limited5.   
Due to the growing burden of NAFLD and the population aging, the number of older adults 
with NAFLD is rising and is expected to rise even more in the next decades.  
There is a general agreement on the fact that presence of NAFLD in young and middle aged 
adults has a negative prognostic meaning because it increases the risk for type-2 diabetes, 
metabolic syndrome and cardiovascular diseases3. However, how the presence of NAFLD at 
old ages affects prognosis and relates to the main geriatric outcomes is still unclear and not 
exhaustively investigated. 
NAFLD and cognition  
Previous evidence demonstrated that middle-aged adults with NAFLD present a greater risk of 
cognitive decline and dementia compared to those without NAFLD. Noteworthy, a large cross-
sectional epidemiological study, enrolling in 4,472 adults aged between 20 and 59 year old 
participating in the NHANES III, found that NAFLD was independently associated with lower 
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cognitive performance independent of CVD and its risk factors9. Carotid atherosclerosis, insulin 
resistance, inflammation and hormonal alterations have been proposed as causal mechanisms 
for this association8, 9. Interestingly, NAFLD was associated with lower brain volume in 766 
middle-aged adults in the Framingham Study10. However, whether a positive association 
between NAFLD and cognitive decline holds also at advanced ages and even longitudinally is 
still unclear. A recent study in individuals aged 60 years or older showed that participants with 
both NAFLD and T2DM had lower cognitive performance, but not those with NAFLD only11. 
Moreover, whether the presence NAFLD at advanced ages (≥ 65 years) should be considered a 
risk factor for subsequent faster cognitive decline remains unknown. Likewise, how NAFLD 
progression or regression overtime in the elderly may affect their rate of cognitive decline has 
never been formally investigated. 
Therefore, using data from 457 community dwelling older adults, living in Pianoro, Northern 
Italy, and followed for 7 years (2003-2010), the present study explored the longitudinal 
association between NAFLD and cognitive decline. Participants with available information 
both at baseline and at 7-year follow-up visit on presence/severity of hepatic steatosis assessed 
using abdominal ultrasound and global cognitive function evaluated using Mini-Mental State 
Examination (MMSE) and without excessive alcohol consumption or other competing causes 
of hepatic steatosis were included. Particularly, the aim of the study was to investigate whether 
the presence/severity of hepatic steatosis at baseline and/or its progression/regression over the 
time of follow-up may be associated with the rate of cognitive decline over the same timeframe, 




Study design and setting  
The Pianoro study is an epidemiological study enrolling men and women aged 65 years or more, 
living in Pianoro, near Bologna, Northen Italy. Detailed characteristics of the study have been 
previously provided12, 13. Briefly, baseline information about lifestyle, risk factors for 
atherosclerosis, previous cardiovascular diseases and drugs were collected by self-reported 
questionnaires. Moreover, participants underwent clinical, laboratory and instrumental 
investigations, including abdominal ultrasound assessment, at the Internal Medicine Unit of the 
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S. Orsola-Malpighi Hospital in Bologna, led by Professor Marco Zoli. Overall, 1142 subjects 
underwent baseline visit and, of these, 476 underwent a 7-year follow up visit. Those who had 
uncomplete longitudinal data on NAFLD and cognitive decline and/or reported a significant 
alcohol consumption (n=19) were excluded. Thus, 457 participants were included in the present 
longitudinal analysis.   
Of note, the joint ethics committee of Bologna University and S. Orsola Malpighi Hospital 
approved the Pianoro Study.  
Participants  
The sample for the present analysis consists of 457 participants aged 65 to 87 (mean ±SD: 
70.9±4.1) years old, of whom 225 (49.2%) were men, with no significant alcohol consumption 
(<two units/day) and available data on hepatic steatosis and cognitive performance both at 
baseline and at 7-year follow up visit.  
Covariates  
Years of education were self-reported and collected as none, five years, eight years, thirteen 
years or more than thirteen year based on the Italian Education System. Specifically, for the 
present analysis, poor education was defined as five years or less.  Alcohol intake was defined 
as the daily use of at least one alcoholic unit (a glass of wine or a pint of beer or a small glass 
of spirit). Smoking status (nonsmokers, former smokers or current smokers) was self-reported. 
Weight in kilograms (kg) and height in meters (m) were assessed and used to calculate BMI 
(kg/m2). Waist circumference was measured in centimeters (cm) with the patient standing at the 
umbilicus level. Activities of Daily Living (ADL) scale14 and Instrumental Activities of Daily 
Living (IADL) scale15 were used to assess functional capacity in basic and more complex 
activities of daily living of the study participants. Hypertension was defined as a systolic blood 
pressure (SBP) ≥140 mmHg and/or a diastolic blood pressure (DBP) ≥90 mmHg, and/or 
patients being treated with antihypertensive medication. Hyperlipidemia was defined as total 
serum cholesterol ≥200 mg/dL and/or LDL cholesterol ≥160 mg/dL and/or HDL cholesterol < 
40 mg/dl and/or any concurrent pharmacologic lipid-lowering treatment16. Diagnosis of 
diabetes was based on a history of diabetes according to the American Diabetes Association 
Criteria, and/or on assumptions of anti-diabetes drugs17. Moreover, baseline insulin was 
measured using an electrochemiluminescence immunoassay (Insulin Elecsys; Roche 
Diagnostics). Baseline insulin resistance was then estimated, according to the homeostasis 
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model assessment (HOMA), using the formula: (fasting insulin [mU/l] x fasting glucose 
[mmol/l])/22.518. Finally, baseline serum levels of interleukin 6 (IL-6) were also measured 
using multiplex beads immunoassay (Bio-Rad Laboratories, Hercules, CA, USA) 19. 
Hepatic steatosis  
The evaluation of steatosis, defined at ultrasound scan, as the presence of “bright liver”, was 
made both at baseline and 7-year follow up visits by two skilled operators using an Esoate-
Ansaldo Technos echograph with a 3.5–5 MHz convex ultrasound probe. In particular, steatosis 
was classified into three degrees: 
-Mild when hyperechogenicity of hepatic parenchyma compared to renal parenchyma was 
present, in absence of attenuation of the ultrasound beam, 
-Moderate when attenuation of the ultrasound beam was present, 
-Severe when a marked attenuation of the ultrasound beam, such as not to make visible the 
portal bifurcation, was present. 
For the present analysis, we categorized presence/severity of hepatic steatosis in 0.absence of 
hepatic steatosis; 1.mild hepatic steatosis; 2.moderate hepatic steatosis; 3.severe hepatic 
steatosis. For each participant, difference in presence/severity of hepatic steatosis between the 
7-year follow up visit and the baseline visit was also calculated. In addition, participants were 
classified into three categories according to their progression, stability or regression in hepatic 
steatosis overtime.   
Cognitive status  
Global cognitive status was assessed using the Mini-mental State Examination (MMSE), a 
standardized 30-point questionnaire extensively used in clinical and research setting to screen 
for cognitive impairment in older adults20. 
Statistical analysis  
Baseline characteristics of the population are presented as mean (± standard deviation, SD), 
median (range interquartile) or number (percentage) in the overall population and according to 
progression, stability or regression in hepatic steatosis overtime. ANOVA or Kruskal-Wallis or 
Chi-square test were used to compare subgroups.  
Generalized estimating equation (GEE) models with 30 minus MMSE total score as the 
dependent variables with a Poisson distribution were used to describe the average longitudinal 
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rate of change in cognitive function over the time of follow – up21. An exchangeable covariance 
structure was assumed. GEE modes were also used to test whether baseline presence/severity 
of hepatic steatosis and/or its progression/regression overtime predicted longitudinal rate of 
change in cognitive function while adjusting for covariates. For all the predictive variables 
“predictor”, “time” and “predictor*time” interaction term were included in the models. Of note, 
because a GEE Poisson model was used with 30-MMSE as the dependent variable, the 
parameter estimates in the result tables have been transformed accordingly to be interpreted 
meaningfully21. 
Finally, a nested sensitivity analysis including only participants with moderate-severe hepatic 
steatosis at baseline was performed.  
All analyses were performed using the SAS statistical package, version 9.3 (SAS institute Inc., 






Hepatic steatosis  
Hepatic steatosis was present at baseline in 211 participants (46.2%). In particular, 127 
participants (27.8%) had mild steatosis, 74 participants (16.2%) had moderate steatosis and 10 
participants (2.2%) had severe steatosis. After 7 years, hepatic steatosis was present in 180 
participants (39.4%). In particular, 122 participants (26.7%) had mild steatosis, 55 participants 
(12%) had moderate steatosis and three participants (0.7%) had severe steatosis. Therefore, on 
average, prevalence and severity of steatosis decreased over the time of the study. Specifically, 
106 participants showed a regression of hepatic steatosis, while only 49 a progression; the 
others were stable. Baseline characteristics for the overall population and according steatosis 
regression, stability or progression are presented in Table 1. Briefly, participants who 
underwent regression in hepatic steatosis overtime started from a higher degree of hepatic 
steatosis at baseline and they had greater baseline BMI, waist circumference and insulin 




Overall, in the present study population median values [interquartile range] of MMSE score 
went from 28 [26–29] at baseline evaluation to 27 [25–29] at the follow up evaluation.  
At baseline, older age and poor education were significantly associated with lower cross-
sectional cognitive performance.  
Moreover, independent of baseline age, sex and education, MMSE significantly declined with 
aging over the follow up (the average longitudinal rate of decline in MMSE, estimated using 
GEE model, was - 0.024 (±0.006) point per year, P < .001). A greater baseline age was 
significantly associated with faster longitudinal cognitive decline (P=.005), while no significant 
sex difference were found (supplemental material S1). 
Baseline presence and severity of hepatic steatosis and cognition  
I also used GEE model to test whether baseline presence and severity of hepatic steatosis was 
associated with cross-sectional cognitive status and/or longitudinal rate of change in cognitive 
status, independent of baseline age, sex and level of education. As shown in Table 2, I found 
no significant cross-sectional or longitudinal associations between baseline presence/severity 
of hepatic steatosis and cognitive status.  
Overtime hepatic steatosis regression, stability or progression and cognition  
Then, I explored the association between hepatic steatosis regression, stability or progression 
over the time of the follow up and rate of change in cognitive status over the same timeframe. 
Firstly, I observed that the difference between MMSE at baseline and MMSE at 7-year follow 
up visit was greater in individuals who presented NAFLD regression over the time of the follow 
up compared to the rest of the population, even after adjusting for baseline age, sex, education, 
baseline presence/severity of hepatic steatosis and baseline MMSE (Figure1). Then, performing 
GEE models, I confirmed that participants who underwent NAFLD regression over the time of 
the study had a more accelerated cognitive decline over the same time of the study, independent 
of baseline age, sex and education (P=.037, Table 3 and Supplemental Material S2). As show 
in Figure 2, participants who underwent steatosis regression overtime (red lines) had steeper 
longitudinal trajectories of decline overtime in MMSE over the 7-year follow up compared to 
the rest of the population (gray lines). This result was confirmed even after adjusting for a 
comprehensive set of potential confounders (fully adjusted model, Table 3). In particular, the 
significant association held also when adjusted for baseline BMI and longitudinal change in 
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BMI as well as baseline waist circumference and longitudinal change in waist circumference 
(Table 3 and Supplemental Materials S3-S4). The results were analogous when adjusting for 
time-varying BMI and time-varying waist circumference (not shown). On the other hand, in the 
present sample population longitudinal change in BMI and longitudinal change in waist 
circumference were not significantly associated with longitudinal rate of decline in cognitive 
status (Supplemental Materials S5-S7). 
Nested sensitivity analysis   
Although all previous analyses were adjusted for baseline severity of hepatic steatosis, because 
participants who underwent NAFLD regression overtime started from a more severe baseline 
degree of hepatic steatosis, I performed a nested sensitivity analysis to definitively exclude that 
it may represent a bias. Therefore, I ran a further analysis including only participants with 
moderate-severe hepatic steatosis at baseline comparing those who underwent NADFL 
regression (n=49) to those who did not (n=35). Although the analysis did not reach statistical 
significance due to the small size of the sample, the results for this nested analyses followed the 
same trend of the overall analysis. Specifically, as shown in Figure 3, those who underwent 
NAFLD regression tend to have a steeper decline in MMSE overtime compare to those who 




Using longitudinal data from a cohort of 457 older adults, the present study investigated 
whether the presence/severity of hepatic steatosis at baseline and/or its progression/regression 
over the time of the follow-up may be associated with the rate of cognitive decline over the 
same timeframe, independent of potential confounders. No significant associations were found 
between presence/severity of hepatic steatosis at baseline and either cross-sectional cognitive 
status or rate of decline overtime in cognitive performance. Moreover, participants who 
underwent regression in the degree of hepatic steatosis over the follow-up time presented 
accelerate cognitive decline over the same timeframe compared to the rest of the population, 
independent of hepatic steatosis severity at baseline and other potential confounders. 
Particularly, such associations remained significant even when adjusting for baseline BMI and 
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longitudinal change in BMI as well as baseline waist circumference and longitudinal change in 
waist circumference.  
NAFLD in middle-aged adults is an undeniable risk factor for type 2 diabetes, metabolic 
syndrome and cardiovascular disease 4, 22. Moreover, the presence of NAFLD in middle-aged 
adults is associated with higher risk of future accelerated cognitive decline, mainly due to 
greater carotid atherosclerosis, insulin resistance and pro-inflammatory status 23-25. However, 
the relationship between NAFLD at advanced ages and cognitive performance has never been 
exhaustively investigated so far. For example, a previous study found that NAFLD associated 
with type 2 diabetes but not NAFLD alone is associated with cross-sectional lower cognitive 
performance in individuals aged 60 years or older 11. In addition, to my best knowledge, this is 
the first study investigating the longitudinal association between NAFLD and cognitive decline 
in older adults.  
Noteworthy, I found that NAFLD regression rather than progression was associated with 
accelerated cognitive decline.  
The biological mechanisms underlying such association remain unclear.  
However, weight loss is recognized as the most effective way to promote liver fat removal 26. 
Moreover, while midlife obesity is mainly considered a risk factor for dementia 27-29, at old ages 
loss of weight has been linked to cognitive decline and development of dementia 30-32. 
Nevertheless, whether the loss of weigh in late life is the result of or contributes to dementia is 
controversial. If fact, loss of weight may occur at a preclinical stage in the disease history and 
begin several years before the diagnosis of the disease. In particular, loss of weight may precede 
the onset of dementia, suggesting that pathological processes underlying loss of weight may 
contribute to the subsequent cognitive decline 33. On the other hand, the loss of weight may be 
the result of the occurrence of a wasting chronic condition rather than the cause (reverse 
causation) 34. Specifically, loss of weight may also be an early manifestation of dementia 35. 
Plausible explanations include malnutrition and increased catabolic status. 
Therefore, a pathologic loss of weight, that is often associated with cognitive decline, may be 
responsible for the disappearance of the liver fat deposits and it may have biased the results of 
my analysis. However, I addressed this issue running an additional analysis including change 
in weight overtime as a covariate and the original findings were confirmed (S8 in Supplemental 
Materials).  
Consistently with the results of the present study, previous researches showed that in the 
geriatric population metabolic syndrome and traditional risk factors for cardiovascular disease 
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relate to adverse outcomes in the opposite direction compared to young and middle-aged 
persons 36, 37. Some examples include the “reverse metabolic syndrome” and the “obesity 
paradox”. In fact, contrary to what happens at younger ages, having metabolic syndrome and/or 
being overweight at advanced ages have been found to be protective from mortality 38-41.   
Loss of weight is also one of the criteria to define the frailty syndrome 42.  
In addition, in a previous research I performed at the Intramural Research Program of the 
National Institute on Aging (NIA/NIH) under the leadership of Dr. Luigi Ferrucci, I found that 
loss of weight rather than weight gain was associated with longitudinal expansion of burden of 
multimorbidity in obese older adults enrolled in the InChianti Study 43.  
Overall, these findings suggest that loss of fatness in the elderly is a maker of impending 
deterioration of physical and cognitive health.  
Another important consideration concerns the regional distribution of adiposity. In fact, it has 
been proposed that visceral adiposity may be a better predictor of cognitive decline compared 
to total body fat mass. Therefore, it was suggested that the combination of central obesity (i.e. 
waist circumference) and overall obesity (i.e. BMI) might be more predictive of cognitive 
performance than either measure alone 44. However, in the present study no significant 
associations were found for either change in BMI or change in waist circumference overtime 
and cognitive decline. In addition, the significant association between change in degree of 
hepatic steatosis and cognitive decline held also while adjusting for both these covariates, 
suggesting that the assessment of change overtime in the degree of hepatic steatosis is even 
more meaningful and informative than the assessment of change in anthropometric measures 
alone.  
Points of strengths of the present study include presence of NAFLD defined by abdomen 
ultrasound (not always available in epidemiological studies on aging) and longitudinal design. 
However, some limitations need to be addressed. First, the study population is from a small 
Italian town, so further studies in larger and different populations are required to validate and 
generalize these findings. Second, more than 50% of the original population enrolled the 
Pianoro Study was excluded from the current analysis because no longitudinal data were 
available (S9 in Supplemental Materials). Since the excluded participants were significantly 
older and sicker (as they were taking a greater number of medications) than the included ones 
(S10 in Supplemental Materials), this may represent a “healthy selection bias”. Moreover, 
competing mortality may have affected my results. However, based on the evidence about the 
paradoxical relationship about adiposity and mortality in the geriatric population that I 
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presented in the body of the discussion, it is reasonable to think that those who died would have 
had NAFLD regression rather than stability or progression so this would actually confirm and 
reinforce my results.  
Furthermore, I acknowledge that, because change in degree of hepatic steatosis and change in 
cognitive status occurred within the same timeframe, cause–effect relationships cannot be 
inferred. Besides, the present study included only one cognitive test, specifically MMSE. Other 
studies are required to test the association across a wider range of cognitive tests. Finally, it 
would be interesting to evaluate the association between longitudinal NAFLD regression or 
progression and the parallel change in physical function. However, in the Pianoro Study no 
longitudinal measures of physical function are available.   
  
In conclusion, this study found that NAFLD regression compared to NAFLD stability or 
progression is associated with accelerated cognitive decline in older adults, independent of 
potential confounders. Although further investigations are required to validate these results and 
to fully understand the underlying biological mechanisms, this study supports the hypothesis of 
a paradoxical relationship between traditional cardiovascular risk factors and adverse outcomes 
in late life.  
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Tables and Figures  
Table1. Baseline of characteristics of the study population in the overall sample (n=457) 
and according to overtime hepatic steatosis regression (n=106), stability (n=302) and 
progression (n=49).  











P value * 
Age (years) 70.9 (±4.1) 71.6 (±4.4) 70.7 (±3.9) 70.5 (±4.1) .108 
Sex (men) 225 (49.2%) 60 (56.6%) 144 (47.7%) 21 (42.8%) .183 
Education ≤5 
years  
281 (61.5%) 72 (67.9%) 177 (58.6%) 32 (65.3%) .201 
Alcohol intake 
(units/day) 
1 [0-1] 1 [0-1] 1 [0-1] 1 [0-1] .225 
Ex-Smokers  149 (32.6%) 42 (39.6%) 92 (30.5%) 15 (30.6%) .213 
Current smokers  45 (9.8%) 8 (7.5%) 32 (10.6%) 5 (10.2%) .660 
ADL deficit 129 (28.3%) 36 (33.9%) 80 (26.5%) 13 (27.1%) .333 
IADL deficit 254 (55.7) 65 (61.3%) 167 (55.3%) 22 (45.8%) .195 
MMSE  28 [26-29] 27 [26-29] 28 [26-29] 27 [25-29] .889 




96.2 (±11.1) 111.4 (±10.0) 94.3 (±11.2) 96.9 (±8.8) <.001 
Hypertension 382 (84.3%) 93 (87.7%) 249 (83.3%) 40 (83.3%)  .544 
Hyperlipidemia  377 (82.5%) 86 (81.1%) 252 (83.4%) 39 (79.6%) .737 
Diabetes  59 (12.9%) 17 (16.0%) 36 (11.9%) 6 (12.2 %) .547 




1.78 [1.26-2.81] 2.23 [1.63-3.11] <.001 




3.93 [2.38-6.00] 3.43 [1.82-6.21] 2.90 [1.96-5.20] .181 
Hepatic steatosis 
severity  
0 [0-1] 1[1-2]  
 




Table 2. Generalized estimating equation (GEE) model testing whether baseline 
presence/severity of hepatic steatosis predicts longitudinal rate of change in cognitive 
status while adjusting for baseline age, sex and level of education. 
  
Cognitive status (MMSE) 
 
 Estimate  Standard error  P value 
Baseline age (years) -0.031  0.009  .001 
Sex (men)  0.007  0.082  .929 
Education ≤ 5 years  -0.687  0.089  <.001 
Baseline presence/severity 
of hepatic steatosis 
0.019  0.048  .683 
Time  -0.024 0.006 <.001 
Baseline age (years) *time -0.004  0.001   .005 
Sex (men)  *time -0.001 0.012 .904 
Education ≤ 5 years *time 0.017 0.013 .201 
Baseline presence/severity 
of hepatic steatosis *time  














Table 3. Generalized estimating equation (GEE) models testing whether regression in 
hepatic steatosis overtime predicts longitudinal rate of change in cognitive status while 
adjusting for covariates. 
  
Cognitive status (MMSE) 
 
 Time Regression in hepatic 
steatosis*time 
 Estimate (SE) P value Estimate (SE) P value 
Model I * 
 
-0.024 (0.006) <.001 -0.036 (0.017) .037 
Model II ** 
 
-0.024 (0.006) <.001 -0.036 (0.017) .036 
Model III *** 
 
-0.023 (0.006) <.001 -0.034 (0.017) .043 
Model IV **** 
 
-0.020 (0.006) .002 -0.040 (0.019) .035 
* adjusted for baseline age, sex, education and baseline severity of hepatic steatosis 
** adjusted for covariates in Model I + baseline BMI and longitudinal change in BMI  
*** adjusted for covariates in Model II + baseline waist circumference and longitudinal change 
in waist circumference  
**** adjusted for covariates in Model III + smoking status, alcohol intake, present or incident 
diabetes, hypertension and hyperlipidemia, baseline and longitudinal change in ADL and 







Figure1. Average longitudinal change in MMSE (MMSE at baseline visit – MMSE at 7-
year follow up visit) according to steatosis regression (red box), stability (black box) or 
progression (blue box) and adjusted for baseline age, sex, level of education, baseline 
presence/severity hepatic steatosis and baseline MMSE score. 
 
Note:  
Regression versus rest of the population: P value <.05 
Regression versus stability: P value <.05 
Regression versus progression: P value >.05 
regression stability progression
NAFLD and cognition overtime

































Figure2. Longitudinal trajectories of decline in MMSE over the 7-year follow up in 
participants who underwent steatosis regression overtime (red lines) versus the rest of the 




Note: P value <.05  
 





















Figure 3. Nested sensitivity analysis including only participants with moderate-severe 
hepatic steatosis at baseline and comparing those who underwent steatosis regression 






















Partecipants with baseline moderate-severe steatosis regression
who underwent regression overtime (n=49)
Partecipants with baseline moderate-severe steatosis regression




S1. Generalized estimating equation (GEE) model estimating the average longitudinal 
rate of decline in MMSE independent of age, sex and education.  
  
Cognitive status (MMSE) 
 
 Estimate  Standard error  P value 
Baseline age (years) -0.031 0.009 .001 
Sex (men)  0.003 0.081 .968 
Education ≤ 5 years  -0.684 0.089 <.001 
Time  -0.024 0.006 <.001 
Baseline age (years) *time -0.004 0.001 .005 
Sex (men)  *time -0.001 0.012 .942 
















S2. Generalized estimating equation (GEE) model testing whether regression in hepatic 
steatosis overtime predicts longitudinal rate of change in cognitive status while adjusting 
for baseline age, sex, education and baseline presence/severity of hepatic steatosis. 
 
  
Cognitive status (MMSE) 
 
 Estimate  Standard error  P value 
Baseline age (years) -0.032 0.009 .001 
Sex (men)  0.008 0.082 .919 
Education ≤ 5 years  -0.685 0.089 <.001 
Baseline presence/severity 
of hepatic steatosis 
0.009 0.065 .894 
 








Time  -0.024 0.006 <.001 
Baseline age (years) *time -0.003 0.001 .018 
Sex (men)  *time -0.003 0.012 .794 
Education ≤ 5 years *time 0.017 0.013 .189 
Baseline presence/severity 





Regression in hepatic 
steatosis*time  










S3. Generalized estimating equation (GEE) model testing whether regression in hepatic 
steatosis overtime predicts longitudinal rate of change in cognitive status while adjusting 
for baseline age, sex, education, baseline presence/severity of hepatic steatosis, baseline 
BMI and change overtime in BMI. 
  
Cognitive status (MMSE) 
 
 Estimate  Standard error  P value 
Baseline age (years) -0.033 0.010 .001 
Sex (men)  0.012 0.082 .882 
Education ≤5 years  -0.682 0.089 <.001 
Baseline BMI  0.002 0.012 .839 
Longitudinal change in 
BMI  
0.011 0.024 .648 
Baseline presence/severity 
of hepatic steatosis 
0.006 0.072 .938 
 








Time  -0.024 0.006 <.001 
Baseline age (years) *time -0.003 0.001 .021 
Sex (men)  *time -0.004 0.012 .719 
Education ≤ 5 years *time 0.018 0.013 .177 
Baseline BMI *time -0.002 0.002 .188 
Longitudinal change in 
BMI *time  
0.001 0.003 .807 
Baseline presence/severity 





Regression in hepatic 
steatosis*time  




S4. Generalized estimating equation (GEE) model testing whether regression in hepatic 
steatosis overtime predicts longitudinal rate of change in cognitive status while adjusting 
for baseline age, sex, education, baseline presence/severity of hepatic steatosis, baseline 
BMI, change overtime in BMI, baseline waist circumference and change overtime in waist 
circumference. 
  
Cognitive status (MMSE) 
 
 Estimate  Standard error  P value 
Baseline age (years) -0.032 0.011 .003 
Sex (men)  0.017 0.084 .843 
Education ≤5 years  -0.674 0.090 <.001 
Baseline BMI  0.017 0.021 .425 
Longitudinal change in 
BMI  
0.021 0.027 .438 
Baseline waist 
circumference  
-0.006 0.007 .369 
Longitudinal change in 
waist circumference  
0.005 0.008 .493 
Baseline presence/severity 
of hepatic steatosis 
0.014 0.072 .845 
 








Time  -0.023 0.006 <.001 
Baseline age (years) *time -0.004 0.002 .013 
Sex (men)  *time -0.001 0.012 .936 
Education ≤ 5 years *time 0.018 0.013 .181 
Baseline BMI *time -0.005 0.003 .075 
Longitudinal change in 
BMI *time  










Longitudinal change in 
waist circumference 
0.001  0.001  .602 
Baseline presence/severity 





Regression in hepatic 
steatosis*time  






















S5. Generalized estimating equation (GEE) model testing whether change overtime in 
BMI predicts longitudinal rate of change in cognitive status while adjusting for baseline 
age, sex, education and baseline BMI. 
  
Cognitive status (MMSE) 
 
 Estimate  Standard error  P value 
Baseline age (years) -0.032 0.010 .001 
Sex (men)  0.011 0.083 .891 
Education ≤5 years  -0.682 0.089 <.001 
Baseline BMI  0.003 0.010 .735 
Longitudinal change in 
BMI  
0.013 0.024 .603 
Time  -0.024 0.006 <.001 
Baseline age (years) *time -0.004 0.001 .009 
Sex (men)  *time -0.003 0.011 .823 
Education ≤ 5 years *time 0.017 0.013 .209 
Baseline BMI *time -0.002 0.001 .185 
Longitudinal change in 
BMI *time  












S6. Generalized estimating equation (GEE) model testing whether change overtime in 
waist circumference predicts longitudinal rate of change in cognitive status while 
adjusting for baseline age, sex, education and baseline waist circumference.  
  
Cognitive status (MMSE) 
 
 Estimate  Standard error  P value 
Baseline age (years) -0.031 0.010 .002 
Sex (men)  0.004 0.085 .956 
Education ≤5 years  -0.683 0.089 <.001 
Baseline waist 
circumference  
-0.001 0.003 .838 
Longitudinal change in 
waist circumference  
0.004 0.007 .617 
Time  -0.024 0.006 <.001 
Baseline age (years) *time -0.004 0.001 .006 
Sex (men)  *time -0.002 0.012 .833 








Longitudinal change in 
waist circumference 










S7. Generalized estimating equation (GEE) model testing whether change overtime in 
BMI and/or change overtime in waist circumference predict longitudinal rate of change 
in cognitive status while adjusting for baseline age, sex, education, baseline BMI and 
baseline waist circumference. 
  
Cognitive status (MMSE) 
 
 Estimate  Standard error  P value 
Baseline age (years) -0.032 0.011 .003 
Sex (men)  -0.018 0.085 .831 
Education ≤5 years  -0.674 0.090 <.001 
Baseline BMI  0.019 0.021 .368 
Longitudinal change in 
BMI  
-0.023 0.027 .392 
Baseline waist 
circumference  
-0.006 0.007 .362 
Longitudinal change in 
waist circumference  
0.006 0.008 .465 
Time  -0.024 0.006 <.001 
Baseline age (years) *time -0.004 0.002 .006 
Sex (men)  *time 0.001 0.012 .929 
Education ≤ 5 years *time 0.015 0.013 .216 
Baseline BMI *time -0.006 0.003 .057 
Longitudinal change in 
BMI *time  








Longitudinal change in 
waist circumference 





S8. Generalized estimating equation (GEE) model testing whether regression in hepatic 
steatosis overtime predicts longitudinal rate of change in cognitive status while adjusting 
for baseline age, sex, education, baseline presence/severity of hepatic steatosis, loss of 
weight overtime and time-varying height. 
  
Cognitive status (MMSE) 
 
 Estimate  Standard error  P value 
Baseline age (years) -0.033 0.010 .001 
Sex (men)  0.007 0.112 .528 
Education ≤5 years  -0.670 0.090 <.001 
Time-varying Height (cm) 0.559 0.777 .471 
Loss of weight (kg) -0.005 0.009 .579 
Baseline presence/severity 
of hepatic steatosis 
0.011 0.066 .871 
Regression in hepatic 
steatosis 
0.028 0.128 .824 
Time  -0.025 0.006 <.001 
Baseline age (years) *time -0.003 0.001 .026 
Sex (men)  *time 0.011 0.016 .466 
Education ≤ 5 years *time 0.017 0.013 .204 
Time-varying Height (cm) 
*time 
0.108  0.098 .267 
Loss of weight (kg) *time 0.001 0.001 .456 
Baseline presence/severity 
of hepatic steatosis *time  
0.006 0.009 .516 
Regression in hepatic 
steatosis *time  






























1142 participants undergoing 
baseline visit 
476 participants undergoing 7-
year follow up visit  
-132 dead  
-118 missing survival 
status  
-416 alive but lost to 
follow-up  
457 participants with complete 
longitudinal data on cognitive 
decline and NAFLD  
-19 censored due to 
missing data   
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S10. Comparison of baseline characteristics between included (n=457) and excluded 
(n=685) participants of the Pianoro study  
 Study Sample 
(n=457) 
Rest of baseline 
population 
(n=685) 
P value  
Age (years) 70.9 (±4.1) 73.5 (±6.1) <.001 
Sex (men) 225 (49.2%) 325 (47.5%) .553 
Education ≤5 years  281 (61.5%) 386 (56.3%) .084 
Ex-Smokers  149 (32.6%) 198 (28.9%) .183 
Current smokers  45 (9.8%) 47 (6.8%) .069 
ADL deficit 129 (28.3%) 208 (39.1%) <.001 
IADL deficit 254 (55.7%) 353 (66.3%) <.001 
MMSE  28 [26-29] 27 [23-28] <.001 
BMI (kg/m2) 26.6 (±3.8) 26.2 (±3.9) .102 
Hypertension 382 (84.3%) 461 (86.5%) .336 
Hyperlipidemia  377 (82.5%) 414 (77.7%) .059 
Diabetes  59 (12.9%) 106 (15.5%) .227 
Previous CV events 23 (5.03%) 52 (7.59%)  .087 
Previous falls  69 (15.1%) 112 (16.3%) .570 
Number of medication 2 [1-4] 3 [2-5] <.001 
≥ 4 medications 116 (25.4%) 278 (40.6%) <.001 
 
 
 
 
 
 
 
 
